Showing 26–40 of 40 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Christoph Lange, Yousra Kherabi, Lorenzo Guglielmetti, Raquel Duarte, Gunar Günther
…G. et al. “Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe”, published in this journal ( 1 Günther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C; Tuberculosis Network European Trials group. Availability of drugs and…
Suman Saurabh, Pankaj Bhardwaj
… the recommendation of a shorter all-oral bedaquiline-based regimen for 9–12 months for multidrug or rifampicin-resistant (MDR/RR) tuberculosis, which replaces the current shorter regimen with injectables. The need for a shorter all-oral regimen had been long-felt by experts.[2] …
Michael Ladna
… anastomosis. Case Description/Methods: A man in his 40s on BPAL-M regimen for MDR pulmonary TB presented to Emergency Department with abdominal pain, vomiting, and cessation of bowel movements. Computed tomography abdomen/pelvis showed small bowel obstruction with a terminal ile…
Asan Medical Center
…objective of this study is to analyze the efficacy of a new regimen using Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin for 24 weeks or Bedaquiline, Pretomanid, Linezolid for 26 weeks for the treatment of MDR/RR-TB through the clinical trial. The BPaL (Bedaquiline, Pretom…
Galo A. Goig, Chloé Loiseau, Nino Maghradze, Kakha Mchedlishvili, Teona Avaliani, et al.
Abstract Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR) TB are threatening global TB control. The World Health Organization has recently endorsed new regimens for the treatment of MDR-TB that rely on the new and repurposed drugs bedaquiline, pretom…
Shaikh M, Patel H
…nificant global health challenge, with multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains posing severe threats to treatment efficacy. Linezolid, a key component of the BPaL (Bedaquiline, Pretomanid and Linezolid) regimen, has demonstrated substantial ef…
Karthick Vedi, N Venkateswaramurthy, P. Dineshkumar, Satheesh Nagendrans
…resistant tuberculosis (TB), including multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB), poses major global health challenges. Conventional regimens achieve only 50-60% success rates compared to 85% in drug-susceptible TB. This review examines recent therap…
Jaya Ranjalkar, Premila M Wilfred, R. Lalitha Priya
…tuberculous drug-induced liver injury (ATDILI) for the HRZE regimen was 12.6% (95% CI, 9.9–15.3%, p < 0.001, I2 = 95.1%).4 The median onset time for HRZE associated ATDILI was 3 weeks4 (in 80% of the studies), versus 20 days.1 However, in contrast to this study,1 in India,4 a maj…
Anjali Krishnan P, Praveen Kumar N, Raghul Raj S, Ankit Kumar Bharti S, J. A. Pulatov
…TB Control Program. Results: Among 163 patients, short-term regimens were used in 30 patients (18.2%), including m-STTR (8.5%), m-STTR with delamanide (1.2%), and 6-month BPaLM (8.5%). Long-term standard regimens were used in 53 patients (32.5%). For XDR-TB, BPaL and BPaLC were u…
… two new recommendations, one on the composition of shorter regimens and one on the use of the BPaL regimen (i.e. bedaquiline, pretomanid and linezolid). In addition, the consolidated guidelines include existing recommendations on treatment regimens for isoniazid-resistant TB and…
… two new recommendations, one on the composition of shorter regimens and one on the use of the BPaL regimen (i.e. bedaquiline, pretomanid and linezolid). In addition, the consolidated guidelines include existing recommendations on treatment regimens for isoniazid-resistant TB and…
Nataliia Lytvynenko, Maryna Pogrebna, Yuliia Senko, Yurii Gamazin, Iana Terleeva
BPaL implementation started in Ukraine in November 2020, with the National Institute for TB and Lung Diseases (TB Institute), under TB Reach “Pilot Study to Evaluate the Effectiveness and Safety of the BPaL Treatment Regimen in Ukraine” project implemented by Organization for App…
Stancil SL, Mirzayev F, Abdel-Rahman SM
…States Food and Drug Administration as part of a multi-drug regimen (with bedaquiline and linezolid, BPaL) and recommended by the World Health Organization (WHO) to treat extensively-resistant (XR-TB) and multi-drug resistant tuberculosis (MDR-TB). Approval was granted through th…
O.B. Pikas, M.A. Semeniuk
…0—45 %. The inclusion of second-line drugs in the treatment regimen of patients with isoniazid-resistant tuberculosis increases the effectiveness of treatment by 11.8 %. The overall effectiveness of treatment of patients with multidrug-resistant tuberculosis (MDR-TB) in the wor…
Preeti Preeti, Ameeta Joshi, Madhuparna Dev
…ezolid, and 11.1% were resistant. Linezolid sensitivity for MDR-TB patients was 88.72% of the cases being sensitive, and 11.28% resistant. Linezolid sensitivity in pre-extensively drug-resistant tuberculosis was 88.27% and 11.73% were resistant. Among 1031 samples, 50 samples tak…